FDA Approval For Novartis’s Sickle Cell Treatment Adakveo

Gains Nod Ahead Of Global Blood Therapeutics’ Contender

 
• By Andrew McConaghie
  
Novartis
Adakveo is Novartis' sixth FDA approval of 2019 • Source: Novartis
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip